Brian Skorney
Stock Analyst at Baird
(3.67)
# 771
Out of 5,072 analysts
119
Total ratings
45.88%
Success rate
8.89%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $13.51 | +62.84% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $20.95 | -28.40% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $46.03 | +34.69% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.48 | +448.52% | 4 | Aug 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $49.55 | +144.20% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $21.17 | +51.16% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $181.94 | +40.16% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $784.61 | -25.19% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $73.13 | -24.79% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $127.51 | -21.57% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $13.02 | +130.50% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $0.26 | +1,792.51% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $13.93 | +43.61% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.64 | +227.23% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $344.57 | -37.60% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $151.58 | +18.75% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $9.63 | +190.76% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $13.26 | +194.12% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $44.49 | +41.60% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $432.17 | -24.80% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $23.70 | -57.81% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $4.54 | +5,847.14% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.03 | +48.88% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.25 | +23,900.00% | 3 | May 7, 2018 |
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $13.51
Upside: +62.84%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $20.95
Upside: -28.40%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $46.03
Upside: +34.69%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.48
Upside: +448.52%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $49.55
Upside: +144.20%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $21.17
Upside: +51.16%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $181.94
Upside: +40.16%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $784.61
Upside: -25.19%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $73.13
Upside: -24.79%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $127.51
Upside: -21.57%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.02
Upside: +130.50%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.26
Upside: +1,792.51%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $13.93
Upside: +43.61%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $7.64
Upside: +227.23%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $344.57
Upside: -37.60%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $151.58
Upside: +18.75%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $9.63
Upside: +190.76%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $13.26
Upside: +194.12%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $44.49
Upside: +41.60%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $432.17
Upside: -24.80%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $23.70
Upside: -57.81%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $4.54
Upside: +5,847.14%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.03
Upside: +48.88%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.25
Upside: +23,900.00%